AIMS: Because sentinel lymph node (SLN) biopsy for breast cancer has become well established, one of the challenges now is to determine which patients require a completion axillary dissection following a positive SLN biopsy. METHODS: A prospective database of patients who underwent SLN biopsy for invasive breast cancer from July 1999 to November 2002 (n = 180) was analysed. Fifty four patients (30%) had one or more positive SLN, and all underwent a completion axillary dissection. This subgroup was further analysed to delineate which factors predicted non-SLN metastasis. RESULTS: Twenty six of the 54 patients with a positive SLN had additional metastases in non-SLNs. Significant variables that predicted non-SLN metastasis included extranodal extension (odds ratio (OR), 17.399; 95% confidence interval (CI), 1.69 to 178.96) and macrometastasis within the SLN (OR, 6.985; 95% CI, 1.291 to 37.785). CONCLUSIONS: In patients with invasive breast cancer and a positive SLN, extranodal extension or macrometastasis within the SLN were both independent predictors of non-SLN involvement.
AIMS: Because sentinel lymph node (SLN) biopsy for breast cancer has become well established, one of the challenges now is to determine which patients require a completion axillary dissection following a positive SLN biopsy. METHODS: A prospective database of patients who underwent SLN biopsy for invasive breast cancer from July 1999 to November 2002 (n = 180) was analysed. Fifty four patients (30%) had one or more positive SLN, and all underwent a completion axillary dissection. This subgroup was further analysed to delineate which factors predicted non-SLN metastasis. RESULTS: Twenty six of the 54 patients with a positive SLN had additional metastases in non-SLNs. Significant variables that predicted non-SLN metastasis included extranodal extension (odds ratio (OR), 17.399; 95% confidence interval (CI), 1.69 to 178.96) and macrometastasis within the SLN (OR, 6.985; 95% CI, 1.291 to 37.785). CONCLUSIONS: In patients with invasive breast cancer and a positive SLN, extranodal extension or macrometastasis within the SLN were both independent predictors of non-SLN involvement.
Authors: M A den Bakker; A van Weeszenberg; A Y de Kanter; F H Beverdam; C Pritchard; Th H van der Kwast; M Menke-Pluymers Journal: J Clin Pathol Date: 2002-12 Impact factor: 3.411
Authors: R Manecksha; A D Hill; B Dijkstra; L Kelly; C D Collins; E McDermott; N J O'Higgins Journal: Ir J Med Sci Date: 2001 Oct-Dec Impact factor: 1.568
Authors: S F Abdessalam; E E Zervos; M Prasad; W B Farrar; L D Yee; M J Walker; W B Carson; W E Burak Journal: Am J Surg Date: 2001-10 Impact factor: 2.565
Authors: Andrew H Strickland; Nicolas Beechey-Newman; Christopher B Steer; Peter G Harper Journal: Crit Rev Oncol Hematol Date: 2002-10 Impact factor: 6.312
Authors: Levent Yeniay; Erdem Carti; Can Karaca; Osman Zekioglu; Ulkem Yararbas; Rasih Yilmaz; Murat Kapkac Journal: Breast Care (Basel) Date: 2012-10 Impact factor: 2.860
Authors: Eva C Gombos; Jayender Jagadeesan; Danielle M Richman; Daniel F Kacher Journal: Magn Reson Imaging Clin N Am Date: 2015-07-08 Impact factor: 2.266
Authors: Francesca Combi; Alessia Andreotti; Anna Gambini; Enza Palma; Simona Papi; Alice Biroli; Stefania Zaccarelli; Guido Ficarra; Giovanni Tazzioli Journal: Breast Cancer (Auckl) Date: 2021-05-10
Authors: Franco Di Filippo; Simona Di Filippo; Anna Maria Ferrari; Raffaele Antonetti; Alessandro Battaglia; Francesca Becherini; Laia Bernet; Renzo Boldorini; Catherine Bouteille; Simonetta Buglioni; Paolo Burelli; Rafael Cano; Vincenzo Canzonieri; Pierluigi Chiodera; Alfredo Cirilli; Luigi Coppola; Stefano Drago; Luca Di Tommaso; Privato Fenaroli; Roberto Franchini; Andrea Gianatti; Diana Giannarelli; Carmela Giardina; Florence Godey; Massimo M Grassi; Giuseppe B Grassi; Siobhan Laws; Samuele Massarut; Giuseppe Naccarato; Maria Iole Natalicchio; Sergio Orefice; Fabrizio Palmieri; Tiziana Perin; Manuela Roncella; Massimo G Roncalli; Antonio Rulli; Angelo Sidoni; Corrado Tinterri; Maria C Truglia; Isabella Sperduti Journal: J Exp Clin Cancer Res Date: 2016-12-08